Palmitoylethanolamide (PEA), also known as palmitamide ethanol , is an endogenous fatty acid amide, belonging to the class of nuclear transcription factor agonizers.PEA has been shown to bind to a nuclear receptor (nuclear receptor) that affects a variety of biological functions related to chronic pain and inflammation, and is a natural anti-inflammatory agent [3].The main target of hexadecamide is thought to be peroxisome proliferation-activated receptor alpha (PPAR- alpha).Report OverviewDue to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Palmitoylethanolamide estimated at USD million in the year 2022, is projected to reach a revised size of USD million by 2028, growing at a CAGR of percent during the forecast period 2022-2028.The USA market for Palmitoylethanolamide is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The China market for Palmitoylethanolamide is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The Europe market for Palmitoylethanolamide is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The global key manufacturers of Palmitoylethanolamide include Gihi Chemicals, Cayman Chemical, Synhwa Pharmachem, PeaCURE, TCI Chemicals and Wuxi Cima Science, etc. In 2021, the global top five players had a share approximately percent in terms of revenue.In terms of production side, this report researches the Palmitoylethanolamide production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.In terms of sales side, this report focuses on the sales of Palmitoylethanolamide by region (region level and country level), by company, by Type and by Application. from 2017 to 2022 and forecast to 2028.